# è…¦é€€åŒ–ç—…ç ”ç©¶å¤§ç¶± (Dementia Research Syllabus)

> ä½¿ç”¨æ­¤æ–‡ä»¶è¿½è¹¤ç ”ç©¶é€²åº¦ã€‚

## ğŸ“Š ç¬¬ä¸€éšæ®µï¼šåŸºç¤èˆ‡åˆ†é¡ (Phase 1: Foundations & Classification)
- [ ] [æ¨¡çµ„ 01ï¼šè…¦é€€åŒ–ç—…å°è«– (Module 01: Introduction to Dementia)](modules/01_intro_dementia.md)
    - [ ] è…¦é€€åŒ–ç—… (Dementia) èˆ‡ èªçŸ¥éšœç¤™ç—‡ (Cognitive Impairment) å®šç¾©
    - [ ] é˜¿èŒ²æµ·é»˜ç—‡ (Alzheimer's Disease - AD)
    - [ ] è¡€ç®¡æ€§ç™¡å‘† (Vascular Dementia - VD)
    - [ ] è·¯æ˜“æ°é«”ç™¡å‘† (Dementia with Lewy Bodies - DLB)
    - [ ] é¡é¡³è‘‰ç™¡å‘† (Frontotemporal Dementia - FTD)

## ğŸ§¬ ç¬¬äºŒéšæ®µï¼šç¥ç¶“ç—…ç†å­¸ (Phase 2: Neuropathology)
- [ ] [æ¨¡çµ„ 02ï¼šç—…ç†æ©Ÿåˆ¶ (Module 02: Neuropathology Mechanisms)](modules/02_neuropathology.md)
    - [ ] æ¾±ç²‰æ¨£è›‹ç™½å‡èªª (Amyloid-beta Hypothesis)
    - [ ] Tau è›‹ç™½éåº¦ç£·é…¸åŒ– (Tau Hyperphosphorylation)
    - [ ] ç¥ç¶“ç‚ç—‡ (Neuroinflammation)

## ğŸ§  ç¬¬ä¸‰éšæ®µï¼šè¨ºæ–·èˆ‡ç”Ÿç‰©æ¨™è¨˜ (Phase 3: Diagnostics & Biomarkers)
- [ ] [æ¨¡çµ„ 03ï¼šè‡¨åºŠè©•ä¼°å·¥å…· (Module 03: Clinical Assessment)](modules/03_clinical_scales.md)
    - [ ] MMSE, MoCA è©•ä¼°è¡¨
    - [ ] è‡¨åºŠå¤±æ™ºè©•å®šé‡è¡¨ (CDR) / å…¨çƒé€€åŒ–é‡è¡¨ (GDS)
- [ ] [æ¨¡çµ„ 04ï¼šç”Ÿç‰©æ¨™è¨˜èˆ‡å½±åƒ (Module 04: Biomarkers & Imaging)](modules/04_biomarkers.md)
    - [ ] è…¦è„Šé«“æ¶² (CSF) æª¢æ¸¬
    - [ ] PET å½±åƒ (Amyloid/Tau PET)
    - [ ] MRI è…¦éƒ¨èç¸®åˆ†æ

## ğŸ’Š ç¬¬å››éšæ®µï¼šæ²»ç™‚èˆ‡å¹²é  (Phase 4: Treatment & Interventions)
- [ ] [æ¨¡çµ„ 05ï¼šè—¥ç‰©æ²»ç™‚ (Module 05: Pharmacotherapy)](modules/05_pharmacotherapy.md)
    - [ ] è†½é¹¼é…¶æŠ‘åˆ¶åŠ‘ (AChEIs)
    - [ ] NMDA å—é«”æ‹®æŠ—åŠ‘
    - [ ] å–®æ ªæŠ—é«”ç™‚æ³• (å¦‚ Aducanumab/Lecanemab)

## ğŸ”¬ ç¬¬äº”éšæ®µï¼šAI èˆ‡å‰æ²¿æŠ€è¡“ (Phase 5: AI & Future Tech)
- [ ] [æ¨¡çµ„ 06ï¼šæ·±åº¦å­¸ç¿’åœ¨å½±åƒè­˜åˆ¥ä¸­çš„æ‡‰ç”¨ (Module 06: AI in Medical Imaging)](modules/06_ai_imaging.md)
- [ ] [æ¨¡çµ„ 07ï¼šå¤§èªè¨€æ¨¡å‹ (LLM) åœ¨èªçŸ¥ç¯©æŸ¥ä¸­çš„æ½›åŠ› (Module 07: LLMs in Screening)](modules/07_llm_screening.md)

---
*æœ€å¾Œæ›´æ–°ï¼š2025å¹´12æœˆ26æ—¥*
